Mode
Text Size
Log in / Sign up

Systematic review and meta-analysis finds no mortality benefit for alternative loop diuretics in chronic heart failureAlternative heart failure diuretics show no mortality benefit but higher risk

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider that alternative loop diuretics show no mortality benefit over furosemide in chronic heart failure, with a noted SAE risk.

This is a systematic review and meta-analysis of randomized trials examining alternative loop diuretics (torsemide, azosemide, piretanide) versus furosemide for chronic heart failure. The synthesis included 23 RCTs with a total of 4902 patients. The authors found no reduction in all-cause mortality with alternative diuretics (risk ratio 1.00, 95% CI 0.89, 1.12; p=0.95) and no reduction in all-cause hospitalizations (risk ratio 0.99, 95% CI 0.84, 1.17; p=0.92). For serious adverse events, a higher risk was observed with alternative diuretics (risk ratio 1.32, 95% CI 1.03, 1.68), based on pooled data for torsemide and piretanide. Body weight change showed no difference in the pooled analysis (mean difference 0.00 kg, 95% CI -1.19, 1.20), though azosemide was associated with a significant weight reduction versus furosemide (mean difference -1.00 kg, 95% CI -1.42, -0.58). The authors note limitations including a limited number of trials with inconsistent SAE definitions and substantial heterogeneity for body weight change (I²=92.43%). Practice relevance is restrained, as the choice of loop diuretic did not influence mortality risk, but caution is advised for SAE risk with torsemide and piretanide.

A large review of 23 clinical trials with over 4,900 heart failure patients compared common diuretics. The study looked at furosemide versus alternatives like torsemide, azosemide, and piretanide. The main goal was to see if any drug could lower the chance of death.

The results showed no clear winner for survival. Patients taking alternative diuretics had about the same risk of death as those on furosemide. There was also no major difference in how often people were hospitalized for any reason. This suggests that for most patients, switching from furosemide may not change these key outcomes.

However, the review found a notable safety issue. Patients on torsemide and piretanide had a higher chance of serious side effects compared to furosemide. The exact number of events was not reported, but the risk was about 30% higher. For body weight, there was no overall difference between the drugs, though one small trial suggested azosemide might lead to slightly more weight loss.

The findings are limited because the trials defined serious side effects differently, and there were not many studies for some comparisons. Doctors should be cautious when considering torsemide or piretanide due to the increased risk of serious problems.

What this means for you:
Alternative diuretics did not improve survival in heart failure, but some raised safety concerns compared to furosemide.

Study Details

Study typeMeta analysis
Sample sizen = 4,902
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
BACKGROUND: Loop diuretics relieve congestion in chronic heart failure (CHF). We systematically reviewed randomised clinical trials (RCTs) evaluating their effects. METHODS: A systematic search was conducted across major databases. We included RCTs that compared a loop diuretic to another loop diuretic, placebo, or "no intervention". The primary outcome was all-cause mortality, and secondary outcomes were all-cause hospitalisation, serious adverse events (SAEs), and change in body weight (kg). RESULTS: This review included 23 RCTs that enrolled 4,902 patients. Treatment with alternative loop diuretics (torsemide, azosemide and piretanide) compared with furosemide did not reduce all-cause mortality (risk ratio 1.00, 95% CI 0.89, 1.12); I = 0%; p = 0.95), nor did it reduce all-cause hospitalisations (risk ratio 0.99, 95% CI 0.84, 1.17); I = 53,46%, p = 0.92). In a pooled analysis of alternative loop diuretics (including torsemide and piretanide) the risk of SAEs was higher compared to furosemide (risk ratio 1.32, 95% CI 1.03, 1.68); I = 0%), although this finding was based on a limited number of trials with inconsistent definitions and should therefore be interpreted cautiously. The pooled meta-analysis of change in body weight did not show a difference between loop diuretics (mean difference 0.00 kg, 95% CI -1.19, 1.20; I = 92.43), indicating substantial heterogeneity. Azosemide resulted in a significant weight loss reduction compared to furosemide (mean difference - 1.00 kg, 95% CI -1.42, -0.58) based on a single small study. CONCLUSIONS: The choice of loop diuretic did not seem to influence the risk of mortality. In a pooled analysis of torsemide and piretanide, the risk of SAEs was higher when compared to furosemide, but the certainty of this finding is limited. Azosemide was associated with weight loss compared to furosemide in one small trial.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.